Personalis, Inc. (NASDAQ:PSNL) Receives Average Recommendation of “Moderate Buy” from Analysts

Personalis, Inc. (NASDAQ:PSNL) has been given a consensus recommendation of “Moderate Buy” by the eight research firms that are currently covering the stock, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and six have assigned a buy recommendation to the company. The average 12 month price objective among analysts that have issued ratings on the stock in the last year is $11.00.

A number of brokerages have recently issued reports on PSNL. Guggenheim boosted their target price on shares of Personalis from $12.00 to $13.00 and gave the company a “buy” rating in a research note on Monday, January 26th. Wall Street Zen upgraded shares of Personalis from a “sell” rating to a “hold” rating in a report on Sunday. Needham & Company LLC boosted their price objective on shares of Personalis from $10.00 to $12.00 and gave the company a “buy” rating in a research report on Friday, February 27th. Weiss Ratings restated a “sell (d-)” rating on shares of Personalis in a research note on Thursday, January 22nd. Finally, BTIG Research raised their target price on shares of Personalis from $12.00 to $13.00 and gave the stock a “buy” rating in a research report on Wednesday, February 11th.

Personalis Stock Performance

Shares of PSNL stock opened at $8.31 on Wednesday. Personalis has a 52-week low of $2.83 and a 52-week high of $11.50. The firm has a market capitalization of $869.48 million, a P/E ratio of -9.13 and a beta of 2.02. The stock has a 50 day moving average price of $8.86 and a 200 day moving average price of $8.19.

Personalis (NASDAQ:PSNL) last announced its quarterly earnings data on Thursday, February 26th. The company reported ($0.26) EPS for the quarter, beating the consensus estimate of ($0.31) by $0.05. Personalis had a negative return on equity of 39.13% and a negative net margin of 116.69%.The company had revenue of $17.35 million for the quarter, compared to the consensus estimate of $17.12 million. As a group, sell-side analysts forecast that Personalis will post -1.4 EPS for the current year.

Institutional Investors Weigh In On Personalis

A number of institutional investors and hedge funds have recently bought and sold shares of the company. Caitong International Asset Management Co. Ltd grew its position in shares of Personalis by 76.1% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 3,423 shares of the company’s stock worth $27,000 after buying an additional 1,479 shares in the last quarter. Deutsche Bank AG raised its holdings in shares of Personalis by 4.5% in the fourth quarter. Deutsche Bank AG now owns 38,827 shares of the company’s stock valued at $309,000 after acquiring an additional 1,655 shares in the last quarter. Royal Bank of Canada lifted its stake in Personalis by 3.2% in the first quarter. Royal Bank of Canada now owns 78,341 shares of the company’s stock worth $275,000 after acquiring an additional 2,395 shares during the period. Howland Capital Management LLC lifted its stake in Personalis by 0.9% in the second quarter. Howland Capital Management LLC now owns 285,308 shares of the company’s stock worth $1,872,000 after acquiring an additional 2,500 shares during the period. Finally, Intech Investment Management LLC grew its holdings in Personalis by 23.4% during the 4th quarter. Intech Investment Management LLC now owns 20,342 shares of the company’s stock worth $162,000 after acquiring an additional 3,851 shares in the last quarter. 61.91% of the stock is owned by institutional investors.

Personalis Company Profile

Personalis, Inc (NASDAQ: PSNL) is a clinical‐stage genomics company that develops and markets advanced next‐generation sequencing (NGS) services and assays designed to accelerate precision medicine. The Company’s core offering is the ImmunoID NeXT™ Platform, which combines comprehensive tumor profiling—including whole exome, transcriptome, and T‐cell receptor sequencing—with proprietary bioinformatics to identify biomarkers and guide immuno‐oncology research. Personalis serves biopharmaceutical companies, academic institutions, and clinical research organizations seeking in‐depth insights into cancer, autoimmune diseases and other complex conditions.

In addition to its flagship ImmunoID NeXT™ Platform, Personalis offers a suite of customizable sequencing assays for biomarker discovery, clinical trial support and companion diagnostic development.